Pelacarsen

Pelacarsen (ISIS 681257; also designated IONIS-APO(a)-LRx, AKCEA-APO(a)-LRx, and TQJ230) is a second-generation, hepatocyte-directed antisense oligonucleotide (ASO) conjugated to a triantennary N-acetylgalactosamine (GalNAc3) ligand, designed to reduce circulating lipoprotein(a) [Lp(a)] concentrations by selective inhibition of apolipoprotein(a) [apo(a)] synthesis in the liver. The compound targets the messenger RNA transcribed from the LPA gene, binding with high specificity and triggering RNase H1-mediated cleavage and subsequent degradation of the transcript, thereby preventing translation of the apo(a) protein that is the defining structural component of the Lp(a) particle. The GalNAc3 conjugation exploits the high-density expression of the asialoglycoprotein receptor (ASGPR) on hepatocyte surfaces to achieve rapid, selective uptake into the liver, the exclusive site of apo(a) biosynthesis, conferring a 20- to 30-fold improvement in potency relative to the unconjugated parent compound IONIS-APO(a)Rx and enabling clinically effective Lp(a) lowering at substantially reduced doses and extended dosing intervals.

Lipoprotein(a) is a genetically determined, independent, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve stenosis (CAVS), and thrombotic events. Plasma Lp(a) concentrations are primarily determined by LPA gene variation and are minimally responsive to lifestyle modification or conventional lipid-lowering pharmacotherapy including statins, ezetimibe, and PCSK9 inhibitors. Approximately 20 to 25 percent of the global population carries Lp(a) concentrations above 50 mg/dL, the threshold at which epidemiological and Mendelian randomization data consistently demonstrate elevated cardiovascular risk. Prior to the development of targeted Lp(a)-lowering agents, no pharmacotherapy had demonstrated selective, potent, and sustained reduction of Lp(a) in a manner suitable for chronic cardiovascular risk management.

In the pivotal Phase 2b dose-ranging trial (Tsimikas et al., 2020, New England Journal of Medicine), pelacarsen administered subcutaneously to 286 patients with established ASCVD and Lp(a) concentrations of 60 mg/dL or greater produced dose-dependent Lp(a) reductions of 35 to 80 percent across five dosing regimens (20 mg every 4 weeks, 40 mg every 4 weeks, 60 mg every 4 weeks, 20 mg every 2 weeks, and 20 mg every week) over 6 to 12 months, with the 20 mg weekly regimen achieving approximately 80 percent mean reduction. The compound was well tolerated; the principal adverse events were mild injection site reactions. On the basis of these results, the 80 mg monthly subcutaneous dose was selected for the Phase 3 cardiovascular outcomes program.

The Lp(a)HORIZON trial (NCT04023552) is a randomized, double-blind, placebo-controlled Phase 3 study enrolling 8,323 patients with established cardiovascular disease and Lp(a) concentrations of 70 mg/dL or greater, designed to evaluate whether pelacarsen 80 mg administered subcutaneously once monthly reduces the incidence of major adverse cardiovascular events (MACE; composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization) relative to placebo on a background of optimized standard-of-care therapy. Enrollment was completed in 2022; topline results are anticipated in 2026. A companion Phase 3 trial (Lp(a)FRONTIERS CAVS) evaluates pelacarsen in calcific aortic valve stenosis progression. This monograph reviews the chemistry, conjugation technology, and molecular pharmacology of pelacarsen; the comprehensive pharmacokinetic record including hepatic impairment and ethnic pharmacokinetic data; the preclinical and clinical evidence base; sourcing and handling considerations; stack interactions; adverse events and safety signal; and a comparative assessment of five Lp(a)-lowering agents against pelacarsen on five competency standards.